BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19728923)

  • 1. [Progress and prospects in cancer stem cell research for hepatocellular carcinoma].
    Xu W; Cao L; Yin ZF
    Ai Zheng; 2009 Sep; 28(9):1004-8. PubMed ID: 19728923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.
    Marquardt JU; Factor VM; Thorgeirsson SS
    J Hepatol; 2010 Sep; 53(3):568-77. PubMed ID: 20646772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
    Ma S; Chan KW; Hu L; Lee TK; Wo JY; Ng IO; Zheng BJ; Guan XY
    Gastroenterology; 2007 Jun; 132(7):2542-56. PubMed ID: 17570225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma.
    Lingala S; Cui YY; Chen X; Ruebner BH; Qian XF; Zern MA; Wu J
    Exp Mol Pathol; 2010 Aug; 89(1):27-35. PubMed ID: 20511115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
    Jia Q; Zhang X; Deng T; Gao J
    Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells.
    Nakayama M; Ogasawara S; Akiba J; Ueda K; Koura K; Todoroki K; Kinoshita H; Yano H
    J Gastroenterol Hepatol; 2014 May; 29(5):1092-101. PubMed ID: 24325739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology and clinical implications of CD133(+) liver cancer stem cells.
    Ma S
    Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma.
    Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD
    World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells.
    Wilson GS; Hu Z; Duan W; Tian A; Wang XM; McLeod D; Lam V; George J; Qiao L
    Stem Cells Dev; 2013 Oct; 22(19):2655-64. PubMed ID: 23638793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
    Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A
    J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
    Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
    Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties.
    Su YJ; Lin WH; Chang YW; Wei KC; Liang CL; Chen SC; Lee JL
    Oncotarget; 2015 Nov; 6(35):38029-45. PubMed ID: 26515729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of cancer stem cell biology in hepatocellular carcinoma.
    Ji J; Wang XW
    Semin Oncol; 2012 Aug; 39(4):461-72. PubMed ID: 22846863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
    Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
    Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122.
    Song K; Kwon H; Han C; Zhang J; Dash S; Lim K; Wu T
    Oncotarget; 2015 Dec; 6(38):40822-35. PubMed ID: 26506419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant Wnt/β-catenin signaling and elevated expression of stem cell proteins are associated with osteosarcoma side population cells of high tumorigenicity.
    Yi XJ; Zhao YH; Qiao LX; Jin CL; Tian J; Li QS
    Mol Med Rep; 2015 Oct; 12(4):5042-8. PubMed ID: 26134785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.
    Zhu Z; Hao X; Yan M; Yao M; Ge C; Gu J; Li J
    Int J Cancer; 2010 May; 126(9):2067-78. PubMed ID: 19711346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
    Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells.
    Liu Z; Dai X; Wang T; Zhang C; Zhang W; Zhang W; Zhang Q; Wu K; Liu F; Liu Y; Wu J
    Cancer Lett; 2017 Aug; 400():149-160. PubMed ID: 28455240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
    Ma YC; Yang JY; Yan LN
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.